|
xB3-002: Glioblastoma
|
3
|
BIOASIS TECHNOLOGIES INC
|
Jun 27, 2018 10:20AM
|
|
Bioasis: An Emerging Medical Market Play with Great Opportunity
|
3
|
BIOASIS TECHNOLOGIES INC
|
Jul 31, 2020 11:01AM
|
|
Re: New Share Price Contest
|
3
|
Resverlogix Corp.
|
Oct 11, 2019 03:42PM
|
|
Re: i would love to hear,..
|
3
|
Resverlogix Corp.
|
Dec 06, 2019 09:01AM
|
|
Re: Here's to New 52 week highs
|
3
|
Resverlogix Corp.
|
Sep 05, 2018 01:41PM
|
|
Re: Biogen/Eisai Scrap Aducanumab
|
3
|
Resverlogix Corp.
|
Mar 21, 2019 03:19PM
|
|
Re: ERA-EDTA 2019 June 13-16
|
3
|
Resverlogix Corp.
|
Jun 12, 2019 08:09PM
|
|
xB3-007 Neurodegeneration
|
3
|
BIOASIS TECHNOLOGIES INC
|
Jun 27, 2018 10:27AM
|
|
Re: Questions for Bear
|
3
|
Resverlogix Corp.
|
Feb 09, 2016 11:57AM
|
|
ESC 2017
|
3
|
Resverlogix Corp.
|
Jun 09, 2017 11:18AM
|
|
Re: From CRP to IL-6 to IL-1: Moving Upstream To Identify Novel Targets for Atheroprotection
|
3
|
Resverlogix Corp.
|
May 11, 2019 10:52PM
|
|
Re: When in Rome.......
|
3
|
Resverlogix Corp.
|
Aug 27, 2016 05:33PM
|
|
Re: RESVERLOGIX EXCEEDS FULL ENROLLMENT FOR THE PIVOTAL PHASE 3 BETONMACE CLINICAL TRIAL
|
3
|
Resverlogix Corp.
|
Mar 19, 2018 07:42AM
|
|
Re: Shrinking MACE event rate
|
3
|
Resverlogix Corp.
|
Jan 20, 2019 05:51PM
|
|
Re: BETonMACE now at 6-month mark
|
3
|
Resverlogix Corp.
|
May 11, 2016 02:23PM
|
|
Re: Standard of Care in BETonMACE
|
3
|
Resverlogix Corp.
|
Mar 19, 2019 09:39AM
|
|
Re: Resverlogix presenting at Vascular Discovery 2019 next week
|
3
|
Resverlogix Corp.
|
May 11, 2019 11:07PM
|
|
Re: Could there be another shoe waiting to drop?
|
3
|
Resverlogix Corp.
|
May 19, 2019 08:54PM
|
|
Re: Zenith AGM
|
3
|
Zenith Epigenetics
|
Aug 22, 2019 07:18PM
|
|
Re: EDITRe: i would love to hear,..
|
3
|
Resverlogix Corp.
|
Dec 06, 2019 09:06AM
|
